Pentixafor PET/CT promising in patients with primary aldosteronism

Monday, December 1 | 8:00 a.m.-8:10 a.m. | M1-SSNMMI02-1 | Room S501

Gallium-68 (Ga-68) pentixafor PET/CT shows high accuracy in detecting aldosterone-producing adenomas (APAs) in patients with primary aldosteronism, according to a study in this scientific session.

Presenter Victor Ohannesian, a medical student at the Albert Einstein Israelite Hospital in São Paulo, Brazil, and colleagues, searched eight published studies on the use of Ga-68 pentixafor PET/CT up to January 2025. They found eight studies with 564 total patients that met their criteria. All of the studies were conducted in China. Bilateral adrenal masses were present in 103 cases, and the median lesion size was 10 mm.

According to the analysis, the pooled sensitivity and specificity of the technique for detecting APAs were 83% and 94% and the diagnostic odds ratio was 27. The area under the curve was 0.91, and the interrater agreement was excellent (κ = 0.93). Significant heterogeneity was found among the studies (I² > 50%, p

Nonetheless, despite heterogeneity and the geographic concentration, Ga-68 pentixafor PET/CT’s high diagnostic accuracy supports its use in surgical planning and patient stratification.

“Integration with biochemical and histological data may enhance diagnostic certainty and reduce reliance on invasive procedures, advancing personalized care in [primary aldosteronism],” Ohannesian and colleagues conclude.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.